Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer
Restricted accessResearch articleFirst published online October, 2022
Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer
To evaluate adherence (as measured by the medication possession ratio) to the first ever course of oral antineoplasic treatment in cancer patients before and after the implementation of a multidisciplinary consultation program (involving an oncologist, a pharmacist, and a nurse) and to investigate the program's impact on adverse events and drug-related problems.
Patients and Methods
In a retrospective single-center study, we compared the medication possession ratio 2 months after treatment initiation in a control group (before multidisciplinary consultation program implementation) versus an interventional group (after multidisciplinary consultation program implementation).
Results
Two months after oral antineoplasic treatment initiation, the mean ± standard deviation medication possession ratio did not differ significantly when comparing the interventional (multidisciplinary consultation program) group (n = 33; 0.99 ± 0.06) with the control group (n = 64; 0.94 ± 0.16) (p = 0.062). Patients in the multidisciplinary consultation program group had fewer adverse events in general (41, vs 109 in the control group; p = 0.048) and digestive adverse events in particular (6 vs 29, respectively; p = 0.007). A total of 53 and 40 drug-related problems were identified in the control and multidisciplinary consultation program groups, respectively (p = 0.074).
Conclusions
Implementation of an multidisciplinary consultation program was not associated with a significant difference in drug adherence (as assessed by the medication possession ratio), which was good before and after implementation. The multidisciplinary consultation program was associated with a lower incidence of adverse events.
WeingartSNBrownEBachPB, et al. NCCN Task force report: oral chemotherapy. J Natl Compr Cancer Netw JNCCN2008; 6: S1–14.
2.
EscaladaPGriffithsP. Do people with cancer comply with oral chemotherapy treatments?Br J Community Nurs2006; 11: 532–536.
3.
PartridgeAH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol2006; 17: 183–184.
4.
RuddyKMayerEPartridgeA. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin2009; 59: 56–66.
5.
DarkowTHenkHJThomasSK, et al. Treatment interruptions and Non-adherence with Imatinib and associated healthcare costs. PharmacoEconomics2007; 25: 481–496.
6.
AllemaniCStormHVoogdAC, et al. Variation in ‘standard care’ for breast cancer across Europe: a EUROCARE-3 high resolution study. Eur J Cancer2010; 46: 1528–1536.
7.
ColNFanaleJEKronholmP. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med1990; 150: 841–845.
8.
PartridgeAH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol Off J Eur Soc Med Oncol2006; 17: 183–184.
9.
AvornJMonetteJLacourA, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA1998; 279: 1458–1462.
10.
GanesanPSagarTGDubashiB, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol2011; 86: 471–474.
11.
HershmanDLShaoTKushiLH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat2011; 126: 529–537.
12.
NieuwlaatRWilczynskiNNavarroT, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev2014; 2014: CD000011.
13.
FoulonVSchöffskiPWolterP. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg2011; 66: 85–96.
14.
AndradeSEKahlerKHFrechF, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf2006; 15: 565–574; discussion 575–577.
15.
GreerJAAmoyalNNisotelL, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist2016; 21: 354–376.
16.
BurkhartPVSabatéE. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh2003; 35: 207.
17.
PartridgeAHAvornJWangPS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst2002; 94: 652–661.
18.
WoodL. A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs2012; 16: 432–438.
19.
Dos SantosMLangeMGervaisR, et al. Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence. Support Care Cancer2019; 27: 3573–3581.
20.
ColomboLRPAguiarPMLimaTM, et al. The effects of pharmacist interventions on adult outpatients with cancer: a systematic review. J Clin Pharm Ther2017; 42: 414–424.
21.
StreicherCDaulangeA. Implementation of pharmacist consultations as part of a multidisciplinary consultation program for patients with oral anticancer agent: a descriptive study. Eur J Oncol Pharm2018; 1: e0003.
22.
Petit-JeanECorreardFMaillanG, et al. Pharmaceutical consultations in oncology: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique – SFPO) guidelines. Eur J Oncol Pharm2019; 2: e11.
23.
MorganKPMulunehBDealAM, et al. Impact of an integrated oral chemotherapy program on patient adherence. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract2018; 24: 332–336.
24.
HinCMHongCC. Oncology pharmacist’s role and impact on the multidisciplinary patient-centre practice of oncology clinic in public hospitals. Asia Pac J Health Manag2019; 14: 16–16.
25.
WongS-FBounthavongMNguyenC, et al. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm2014; 71: 960–965.
26.
SolomonJMAjewoleVBSchneiderAM, et al. Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center. J Oncol Pharm Pract2019; 25: 1564–1569.
27.
BertrandBde GrasseCChevrierR, et al. Recommandations S.F.P.O. sur la réalisation de consultations pharmaceutiques en oncologie. Société Française de Pharmacie Oncologique2017; 10: 1–10.
28.
AllenetBBedouchPRoseF-X, et al. Validation of an instrument for the documentation of clinical pharmacists’ interventions. Pharm World Sci PWS2006; 28: 181–188.
VoTH. Evaluation of the potential impact of pharmacist interventions: development and validation of the CLEO multidimensional tool. 254.
32.
PatelJMHolleLMClementJM, et al. Impact of a pharmacist-led oral chemotherapy-monitoring program in patients with metastatic castrate-resistant prostate cancer. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract2016; 22: 777–783.
33.
MoulinSMMEutrópioFJSouzaJ de O, et al. The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Support Care Cancer Off J Multinatl Assoc Support Care Cancer2017; 25: 951–955.
34.
KinnaerL-MDecoeneEHeckeAV, et al. Collaborative network to take responsibility for oral anticancer therapy (CONTACT): study-protocol investigating the impact of a care pathway. J Adv Nurs2019; 75: 3726–3739.
35.
BourmaudAHeninETinquautF, et al. Adherence to oral anticancer chemotherapy: what influences patients’ over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods. BMC Res Notes2015; 8: 291.
36.
MayPFigginsB. Oral anticancer therapy: a comprehensive assessment of patient perceptions and challenges. J Community Support Oncol2016; 14: 112–116.
37.
SantoleriFLasalaRLogrecoA, et al. Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia. J Oncol Pharm Pract2019; 25: 1035–1041.
38.
LamMSCheungN. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract2016; 22: 741–748.
39.
ViraniASchleiZGleasonC, et al. Impact of an oncology clinical pharmacist specialist in an outpatient multiple myeloma clinic. Clin Lymphoma Myeloma Leuk2020; 20: e543–e546.
40.
SegalEMBatesJFleszarSL, et al. Demonstrating the value of the oncology pharmacist within the healthcare team. J Oncol Pharm Pract2019; 25: 1945–1967.
41.
HolleLMSegalEMJeffersKD. The expanding role of the oncology pharmacistPharmacy2020; 8: 130.
42.
VulajVHoughSBedardL, et al. Oncology pharmacist opportunities: closing the gap in quality care. J Oncol Pract2018; 14: e403–e411.
43.
EdcL-DCgsO-CLgdslM, et al. Use of pharmacy records to measure treatment adherence: a critical review of the literature. Cad Saude Publica2017; 33: e00136216–e00136216.
44.
CanfieldSLZuckermanAAnguianoRH, et al. Navigating the wild west of medication adherence reporting in specialty pharmacy. J Manag Care Spec Pharm2019; 25: 1073–1077.
45.
SattlerELPLeeJSPerriM. Medication (Re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging2013; 30: 383–399.
46.
YeohTTSiPChewL. The impact of medication therapy management in older oncology patients. Support Care Cancer Off J Multinatl Assoc Support Care Cancer2013; 21: 1287–1293.
47.
DenoisVRPoirsonJNourissatA, et al. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care (Engl)2011; 20: 520–527.
48.
KhrystolubovaNShiehMPatelAJ, et al. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. J Oncol Pharm Pract2020; 26: 13–22.
49.
JacobsJMPensakNASpornNJ, et al. Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. J Oncol Pract2017; 13: e474–e485.
50.
PutsMTETuHATourangeauA, et al. Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol2014; 25: 564–577.
51.
FerraciniACRodriguesATde BarrosAA, et al. Prescribing errors intercepted by pharmacist intervention in care of patients hospitalised with breast and gynaecological cancer at a Brazilian teaching hospital. Eur J Cancer Care (Engl)2018; 27(1). DOI: 10.1111/ecc.12767.
52.
EdwardsSJAbbottREdwardsJ, et al. Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. J Pharm Pract2014; 27: 46–52.
53.
CrespoATyszkaM. Evaluating the patient-perceived impact of clinical pharmacy services and proactive follow-up care in an ambulatory chemotherapy unit. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract2017; 23: 243–248.
54.
NgTBadryNde LemosML. Rationalizing the use of auxiliary label for oral oncology drugs. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract2017; 23: 338–343.
55.
BabinMFolliardCRobertJ, et al. [Pharmaceutical consultations in oncology: implementation, one-year review and outlooks]. Ann Pharm Fr2019; 77: 426–434.
56.
RhinehartHEPhillipsMAWadeN, et al. Evaluation of the clinical impact of concomitant acid suppression therapy in colorectal cancer patients treated with capecitabine monotherapy. J Oncol Pharm Pract2019; 25: 1839–1845.
57.
ValeroSSimetGFauchierT, et al. [Non-programmed hospitalization of elderly patients with cancer: which care pathway?]. Bull Cancer (Paris)2019; 106: 293–303.
